Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Minimal Disease Activity as a Treatment Target in Psoriatic Arthritis: A Review of the Literature
Laure Gossec, Dennis McGonagle, Т. В. Коротаева, et al.
The Journal of Rheumatology (2017) Vol. 45, Iss. 1, pp. 6-13
Open Access | Times Cited: 87

Showing 1-25 of 87 citing articles:

EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update
Laure Gossec, Xenofon Baraliakos, Andreas Kerschbaumer, et al.
Annals of the Rheumatic Diseases (2020) Vol. 79, Iss. 6, pp. 700.1-712
Open Access | Times Cited: 834
Difficult-to-treat psoriatic arthritis (D2T PsA): a scoping literature review informing a GRAPPA research project
Shikha Singla, André Lucas Ribeiro, Murat Torğutalp, et al.
RMD Open (2024) Vol. 10, Iss. 1, pp. e003809-e003809
Open Access | Times Cited: 18
Systemic Immune Inflammation Index as a Reliable Disease Activity Marker in Psoriatic Arthritis
Ayse Bahar Kelesoglu Dincer, Serdar Sezer
Journal of College of Physicians And Surgeons Pakistan (2022) Vol. 32, Iss. 06, pp. 773-778
Open Access | Times Cited: 42
Comparing patient-perceived and physician-perceived remission and low disease activity in psoriatic arthritis: an analysis of 410 patients from 14 countries
Clémence Gorlier, Ana‐Maria Orbai, Déborah Puyraimond‐Zemmour, et al.
Annals of the Rheumatic Diseases (2018) Vol. 78, Iss. 2, pp. 201-208
Open Access | Times Cited: 74
Psoriatic Arthritis in Males and Females: Differences and Similarities
Ennio Lubrano, Silvia Scriffignano, Mauro Fatica, et al.
Rheumatology and Therapy (2023) Vol. 10, Iss. 3, pp. 589-599
Open Access | Times Cited: 21
Difficult-to-treat psoriatic arthritis: moving out of the rheumatoid arthritis shadow
Stefan Siebert, Helena Marzo‐Ortega
Nature Reviews Rheumatology (2024) Vol. 20, Iss. 3, pp. 135-136
Closed Access | Times Cited: 7
Janus kinase inhibitors in immuno-inflammatory rheumatic diseases: new opportunities and prospects
Е. Л. Насонов, А. М. Лила
Rheumatology Science and Practice (2019) Vol. 57, Iss. 1, pp. 8-16
Open Access | Times Cited: 52
Gender-related differences in disease activity and clinical features in patients with peripheral psoriatic arthritis: A multi-center study
Mehmet Tuncay Duruöz, Halise Hande Gezer, Kemal Nas, et al.
Joint Bone Spine (2021) Vol. 88, Iss. 4, pp. 105177-105177
Closed Access | Times Cited: 36
Difficult to Treat and Refractory to Treatment in Psoriatic Arthritis
Ennio Lubrano, Silvia Scriffignano, Fabio Massimo Perrotta
Rheumatology and Therapy (2023) Vol. 10, Iss. 5, pp. 1119-1125
Open Access | Times Cited: 16
Comparative efficacy and safety of bimekizumab in psoriatic arthritis: a systematic literature review and network meta-analysis
Philip J. Mease, Dafna D. Gladman, Joseph F. Merola, et al.
Lara D. Veeken (2024) Vol. 63, Iss. 7, pp. 1779-1789
Open Access | Times Cited: 5
Efficacy and safety of guselkumab in patients with active psoriatic arthritis who had inadequate efficacy and/or intolerance to one prior tumor necrosis factor inhibitor: study protocol for SOLSTICE, a phase 3B, multicenter, randomized, double-blind, placebo-controlled study
Alexis Ogdie, Joseph F. Merola, Philip J. Mease, et al.
BMC Rheumatology (2024) Vol. 8, Iss. 1
Open Access | Times Cited: 5
Guselkumab: the First Selective IL-23 Inhibitor for Active Psoriatic Arthritis in Adults
Wolf‐­Henning Boehncke, Nicolò Costantino Brembilla, Michael J. Nissen
Expert Review of Clinical Immunology (2020) Vol. 17, Iss. 1, pp. 5-13
Closed Access | Times Cited: 35
Long-term effectiveness and persistence of ustekinumab and TNF inhibitors in patients with psoriatic arthritis: final 3-year results from the PsABio real-world study
Laure Gossec, Stefan Siebert, Paul Bergmans, et al.
Annals of the Rheumatic Diseases (2022) Vol. 82, Iss. 4, pp. 496-506
Open Access | Times Cited: 17
Association of clinical variables with methotrexate response in patients with psoriatic arthritis
Fazira R. Kasiem, LJ Tucker, Laura C. Coates, et al.
Scandinavian Journal of Rheumatology (2025), pp. 1-8
Open Access
Efficacy and safety of izokibep in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study
Peter C. Taylor, Philip J. Mease, Kurt de Vlam, et al.
Annals of the Rheumatic Diseases (2025)
Open Access
Measurement properties of the minimal disease activity criteria for psoriatic arthritis
Laura C. Coates, Vibeke Strand, Hilary Wilson, et al.
RMD Open (2019) Vol. 5, Iss. 2, pp. e001002-e001002
Open Access | Times Cited: 29
Evaluation of normal cadaveric Achilles tendon and enthesis with ultrashort echo time (UTE) magnetic resonance imaging and indentation testing
Bimin Chen, Xin Cheng, Erik W. Dorthé, et al.
NMR in Biomedicine (2018) Vol. 32, Iss. 1
Open Access | Times Cited: 28
Minimal disease activity (MDA) in patients with recent-onset psoriatic arthritis: predictive model based on machine learning
Rubén Queiró, Daniel Seoane‐Mato, A. Laíz, et al.
Arthritis Research & Therapy (2022) Vol. 24, Iss. 1
Open Access | Times Cited: 15
Effect of Achieving Minimal Disease Activity on the Progression of Subclinical Atherosclerosis and Arterial Stiffness: A Prospective Cohort Study in Psoriatic Arthritis
I. T. Cheng, Qing Shang, Edmund K. Li, et al.
Arthritis & Rheumatology (2018) Vol. 71, Iss. 2, pp. 271-280
Closed Access | Times Cited: 26
Prevalence of Psoriatic Arthritis Patients Achieving Minimal Disease Activity in Real-world Studies and Randomized Clinical Trials: Systematic Review with Metaanalysis
Mariele Zardin-Moraes, André Luís Ferreira Azeredo Da Silva, Carla Forgiarini Saldanha, et al.
The Journal of Rheumatology (2019) Vol. 47, Iss. 6, pp. 839-846
Open Access | Times Cited: 25
Comorbidities, pain and fatigue in psoriatic arthritis, psoriasis and healthy controls: a clinical cohort study
Christine Ballegaard, Marie Skougaard, Jørgen Guldberg–Møller, et al.
Lara D. Veeken (2020) Vol. 60, Iss. 7, pp. 3289-3300
Open Access | Times Cited: 22
Effectiveness of IL-12/23 inhibition (ustekinumab) versus tumour necrosis factor inhibition in psoriatic arthritis: observational PsABio study results
Josef S Smolen, Stefan Siebert, Т. В. Коротаева, et al.
Annals of the Rheumatic Diseases (2021) Vol. 80, Iss. 11, pp. 1419-1428
Open Access | Times Cited: 20
Axial Spondyloarthritis: Evolving concepts regarding the disease's diagnosis and treatment
Alexandros A. Drosos, Aliki I. Venetsanopoulou, Paraskevi V. Voulgari
European Journal of Internal Medicine (2023) Vol. 117, pp. 21-27
Closed Access | Times Cited: 8
Definition of minimal disease activity in psoriasis
G. Carretero, J.M. Carrascosa, L. Puig, et al.
Journal of the European Academy of Dermatology and Venereology (2020) Vol. 35, Iss. 2, pp. 422-430
Closed Access | Times Cited: 19
Validation and clinical interpretability of PsAID - psoriatic arthritis impact of disease
Elziane da Cruz Ribeiro e Souza, Sueli Coelho da Silva Carneiro, Michel Alexandre Yazbek, et al.
Advances in Rheumatology (2020) Vol. 60, Iss. 1
Open Access | Times Cited: 19
Page 1 - Next Page

Scroll to top